P2.03-08 Molecular Spectrum of Patients with MSH2 Mutations in Chinese Non-Small Cell Lung Cancer
W. Wang,C. Xu,Q. Zhang,W. Zhuang,Y. Zhu,Y. Chen,M. Fang,G. Chen,T. Lv,Y. Song
DOI: https://doi.org/10.1016/j.jtho.2018.08.1195
IF: 20.121
2018-01-01
Journal of Thoracic Oncology
Abstract:Although inactivation of MutS Homolog 2 (MSH2) genes may predict sensitivity to immunotherapy in non-small cell lung cancer. little is known about their etiology and prognosis in non-small-cell lung cancer (NSCLC). The aim of this study is to investigate mutations and prognosis of NSCLC harboring MSH2 mutations. A total of 326 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of MSH2 mutation or other genes were detected by next generation sequencing. MSH2 gene mutation rate was 9.51% (31/326) in non-small cell lung cancer, including H839R (5 patients), L390F (4 patients), E809K (3 patients), I169V (3 patients), I544M (1 patient), R217C (1 patient), T8M (1 patient), T552S (1 patient), A189S (1 patient), Q493P (1 patient), I735V (1 patient), A45T (1 patient), A573T (1 patient), R534L (1 patient), V712Sfs*5 (1 patient), F58L (1 patient), S676L (1 patient), N583S (1 patient), I766V plus A2V (1 patient) and Q419K plus Q629R (1 patient), and median overall survival (OS) for these patients was 16.0 months. Among them, all patients were MSH2 gene with co-occurring mutation. Briefly, patients with (n=6) or without (n=25) co-occurring EGFR mutations had a median OS of 6.5 months and 17.0 months respectively (P=0.02); patients with (n=20) or without (n=11) co-occurring TP53 mutations had a median OS of 14.0 months and 17.0 months respectively (P=0.85). MSH2 is involved in MMR, controlling several aspects of genome stability. Immunotherapy may displayed moderated efficacy in patients with MSH2 mutation. EGFR accompanied mutations might play a good prognosis in MSH2 gene mutation NSCLC.